NCT06194565View on ClinicalTrials.gov

99mTc-ABH2 SPECT/CT in Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

December 30, 2023

Study Completion Date

January 30, 2024

Conditions
Breast Cancer
Interventions
DRUG

99mTc-ABH2

Each patient will receive an intravenous injection of 99mTc-ABH2, and undergo a SPECT/CT scan within specified time.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER